Menopausal Status Contributes to Overall Survival in Endometrial Cancer Patients.
Cox proportional hazards model
endometrial cancer
menopause
overall survival
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2023
10 Jan 2023
Historique:
received:
10
10
2022
revised:
28
12
2022
accepted:
09
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Endometrial cancer is the most common female genital tract malignancy in developed countries that occurs predominantly in postmenopausal women. The primary objective of our research was to investigate whether menopause status together with selected conventional prognostic indicators may contribute to overall (all-cause) survival in endometrial cancer patients. For this purpose, we applied the Cox proportional hazards regression model. Patients in advanced FIGO stage showed a relatively poor survival rate. The time since last menstruation and postoperative FSH concentration were identified as unfavorable prognostic factors in our model. Additionally, age at diagnosis, BMI value, adjuvant treatment (brachytherapy), and parity showed no impact on survival. To our knowledge, this is the first study to report a prognostic model for endometrial cancer including exact time from last menstruation as one of the prognostic variables. Due to the fact that there are no stratifying systems to reliably predict survival in patients with endometrial cancer, there is a strong need to revise and update existing models using complementary prognostic indicators. Collection of precise data on various risk factors may contribute to increased accuracy of artificial intelligence algorithms in order to personalize cancer care in the near future.
Identifiants
pubmed: 36672399
pii: cancers15020451
doi: 10.3390/cancers15020451
pmc: PMC9856958
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical University of Lublin
ID : DS 120/2020-2022
Références
Int J Gynaecol Obstet. 2021 Mar;152(3):433-438
pubmed: 33118172
Endocr Relat Cancer. 2008 Jun;15(2):485-97
pubmed: 18509001
Front Surg. 2021 Oct 22;8:704235
pubmed: 34746222
Post Reprod Health. 2016 Jun;22(2):56-8
pubmed: 27363743
Aust N Z J Obstet Gynaecol. 2021 Apr;61(2):275-283
pubmed: 33403680
Arch Gynecol Obstet. 2010 Apr;281(4):709-15
pubmed: 19777250
Int J Environ Res Public Health. 2022 Jul 25;19(15):
pubmed: 35897440
Am J Obstet Gynecol. 2014 Apr;210(4):363.e1-363.e10
pubmed: 24361787
Medicine (Baltimore). 2021 Sep 24;100(38):e27305
pubmed: 34559145
Arch Gen Psychiatry. 2001 Jun;58(6):529-34
pubmed: 11386980
Gynecol Endocrinol. 2020 Aug;36(8):693-697
pubmed: 32208770
Cancer Manag Res. 2021 Nov 27;13:8879-8886
pubmed: 34866940
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Br J Cancer. 2016 Nov 22;115(11):1296-1303
pubmed: 27824810
Maturitas. 2021 Aug;150:37-41
pubmed: 34274074
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
J Obstet Gynaecol Res. 2021 Feb;47(2):560-569
pubmed: 33197987
Front Med (Lausanne). 2022 Apr 14;9:808037
pubmed: 35492356
J Gynecol Oncol. 2018 Jan;29(1):e9
pubmed: 29185267
PLoS One. 2020 Jun 23;15(6):e0235174
pubmed: 32574226
Cancers (Basel). 2022 Aug 22;14(16):
pubmed: 36011034
Am J Obstet Gynecol. 2018 Aug;219(2):181.e1-181.e6
pubmed: 29792852
Int J Gynecol Cancer. 2001 Nov-Dec;11(6):483-7
pubmed: 11906553
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S93-S113
pubmed: 30550486
Onco Targets Ther. 2019 Nov 19;12:9947-9956
pubmed: 31819491
Ginekol Pol. 2011 Oct;82(10):743-8
pubmed: 22379937
PLoS One. 2020 Nov 24;15(11):e0242733
pubmed: 33232359
Lancet. 2000 Apr 22;355(9213):1404-11
pubmed: 10791524
J Pathol. 2018 Apr;244(5):538-549
pubmed: 29344951
Int J Gynaecol Obstet. 2022 Oct;159(1):21-42
pubmed: 35152421
Am J Epidemiol. 1998 Dec 15;148(12):1195-205
pubmed: 9867266